IPSU
Based on 1 publication(s) in Google Scholar
IPSU is a selective, orally available and brain penetrant OX2R antagonist with a pKi of 7.85.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 98.0%
- CAS No.: 1373765-19-5
- Formule: C23H27N5O2
- Masse moléculaire:405.49
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-19914
MK-1064OX2R Antagonist -
HY-100452
TCS-OX2-29OX2R Antagonist -
HY-109012
SeltorexantOrexin-2 Receptor Antagonist -
HY-19320
Orexin 2 Receptor AgonistOX2R Agonist -
HY-10896
JNJ-10397049OX2R Antagonist -
HY-10805
AlmorexantOrexin Receptor Antagonist -
HY-101834
ACT-462206Orexin Receptor Antagonist -
HY-15653
FilorexantOX Receptor Antagonist -
HY-12301
MK-3697OX2R Antagonist -
HY-10895
SB-334867OX1 Receptor Antagonist -
HY-10806
SB-649868OX1/OX2 Receptor Antagonist -
HY-10900
TCS 1102OX Receptor Antagonist
Publications Citing Use of MedChemExpress (MCE) IPSU
MoreVoir tous les produits spécifiques à Isoform Orexin Receptor (OX Receptor)
More
Activité biologique
Description
IC50 & Target
pKi: 7.85 (OX2R), 6.29 (OX1R)[1]
In Vitro
Orexin receptor antagonists represent attractive targets for the development of drugs for the treatment of insomnia. IPSU binds rapidly and reaches equilibrium very quickly in binding and/or functional assays[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1373765-19-5
-
Appearance Solid
-
Masse moléculaire 405.49
-
Formule C23H27N5O2
-
Color White to off-white
-
SMILES
COC1=CC=NC(N(CC2)CCC2(C3=O)CCCN3CC4=CNC5=CC=CC=C54)=N1
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Molecules
2020 Feb 25;25(5):1018. PMID: 32106419
Solvant et solubilité
In Vitro:
DMSO : ≥ 30 mg/mL (73.98 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (275 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Betschart C, et al. Identification of a novel series of orexin receptor antagonists with a distinct effect on sleeparchitecture for the treatment of insomnia. J Med Chem. 2013 Oct 10;56(19):7590-607. [Content Brief]
[2]. Callander GE, et al. Kinetic properties of "dual" orexin receptor antagonists at OX1R and OX2R orexin receptors. Front Neurosci. 2013 Dec 3;7:230. [Content Brief]
[3]. Hoyer D, et al. Distinct effects of IPSU and suvorexant on mouse sleep architecture. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.4662 mL | 12.3308 mL | 24.6615 mL | 61.6538 mL |
| 5 mM | 0.4932 mL | 2.4662 mL | 4.9323 mL | 12.3308 mL | |
| 10 mM | 0.2466 mL | 1.2331 mL | 2.4662 mL | 6.1654 mL | |
| 15 mM | 0.1644 mL | 0.8221 mL | 1.6441 mL | 4.1103 mL | |
| 20 mM | 0.1233 mL | 0.6165 mL | 1.2331 mL | 3.0827 mL | |
| 25 mM | 0.0986 mL | 0.4932 mL | 0.9865 mL | 2.4662 mL | |
| 30 mM | 0.0822 mL | 0.4110 mL | 0.8221 mL | 2.0551 mL | |
| 40 mM | 0.0617 mL | 0.3083 mL | 0.6165 mL | 1.5413 mL | |
| 50 mM | 0.0493 mL | 0.2466 mL | 0.4932 mL | 1.2331 mL | |
| 60 mM | 0.0411 mL | 0.2055 mL | 0.4110 mL | 1.0276 mL |
IPSU Related Classifications
HY-13796 Related Classifications
Powered by Bioz